000518.SZ
Jiangsu Sihuan Bioengineering Co., Ltd [000518.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
000518.SZ Stock Summary
Top 10 Correlated ETFs
000518.SZ
Top 10 Correlated Stocks
000518.SZ
In the News
000518.SZ Financial details
Company Rating
Neutral
Market Cap
2.38B
Income
-60.14M
Revenue
253.46M
Book val./share
0.5
Cash/share
0.02
Dividend
-
Dividend %
-
Employees
250
Optionable
No
Shortable
Yes
Earnings
30 Apr 2021
P/E
-54.47
Forward P/E
-
PEG
-9.56
P/S
12.92
P/B
6.37
P/C
103.5
P/FCF
-102.74
Quick Ratio
1.02
Current Ratio
4.44
Debt / Equity
0.1
LT Debt / Equity
0.05
-
-
EPS (TTM)
-0.06
EPS next Y
-
EPS next Q
-
EPS this Y
39.25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.61%
Revenue last 5Y
-7.34%
Revenue Q/Q
-9.12%
EPS Q/Q
-70.49%
-
-
-
-
SMA20
-33.33%
SMA50
-33.33%
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
-9%
ROE
-11%
ROC
-0.11%
Gross Margin
71%
Oper. Margin
-24%
Profit Margin
-24%
Payout
-1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.72-4.57
52W High
-48.25%
52W Low
+107%
RSI
35
Rel Volume
0.28
Avg Volume
35.05M
Volume
9.83M
Perf Week
-13.03%
Perf Month
-13.75%
Perf Quarter
-20.99%
Perf Half Y
-26.86%
-
-
-
-
Beta
0.546
-
-
Volatility
0.12%, 0.22%
Prev Close
-0.96%
Price
2.07
Change
-2.36%
000518.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.38 | 0.41 | 0.49 | 0.34 | 0.26 | |
| Net income per share | -0.03 | 0.01 | 0.03 | -0.04 | -0.05 | |
| Operating cash flow per share | 0.02 | 0.06 | 0.1 | 0 | 0 | |
| Free cash flow per share | 0.02 | 0.04 | 0.09 | -0.01 | 0 | |
| Cash per share | 0.04 | 0.03 | 0.03 | 0.04 | 0.03 | |
| Book value per share | 0.58 | 0.6 | 0.62 | 0.59 | 0.54 | |
| Tangible book value per share | 0.59 | 0.59 | 0.62 | 0.59 | 0.53 | |
| Share holders equity per share | 0.58 | 0.6 | 0.62 | 0.59 | 0.54 | |
| Interest debt per share | 0.07 | 0.02 | 0.05 | 0.05 | 0.05 | |
| Market cap | 3.43B | 3.74B | 5.27B | 3.74B | 3.26B | |
| Enterprise value | 3.46B | 3.7B | 5.23B | 3.75B | 3.28B | |
| P/E ratio | -116.43 | 260.79 | 193.12 | -97.65 | -61.25 | |
| Price to sales ratio | 8.67 | 8.94 | 10.43 | 10.65 | 12.08 | |
| POCF ratio | 151.89 | 63.74 | 52.59 | 24.01K | 670.74 | |
| PFCF ratio | 207.83 | 86.03 | 57.59 | -496.26 | -904.32 | |
| P/B Ratio | 5.72 | 6.09 | 8.23 | 6.17 | 5.86 | |
| PTB ratio | 5.72 | 6.09 | 8.23 | 6.17 | 5.86 | |
| EV to sales | 8.74 | 8.85 | 10.35 | 10.69 | 12.16 | |
| Enterprise value over EBITDA | 1.7K | 62.57 | 105.19 | -1.72K | -222.19 | |
| EV to operating cash flow | 153.25 | 63.11 | 52.21 | 24.09K | 674.97 | |
| EV to free cash flow | 209.69 | 85.18 | 57.17 | -497.98 | -910.02 | |
| Earnings yield | -0.01 | 0 | 0.01 | -0.01 | -0.02 | |
| Free cash flow yield | 0 | 0.01 | 0.02 | 0 | 0 | |
| Debt to equity | 0.12 | 0.03 | 0.08 | 0.08 | 0.09 | |
| Debt to assets | 0.08 | 0.02 | 0.06 | 0.06 | 0.07 | |
| Net debt to EBITDA | 15.05 | -0.63 | -0.78 | -5.96 | -1.39 | |
| Current ratio | 2.7 | 2.98 | 4.86 | 5.13 | 4.86 | |
| Interest coverage | -9.91 | 11.73 | 40.14 | -32.96 | -54.4 | |
| Income quality | -0.76 | 3.35 | 3.62 | 0 | -0.09 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.09 | 0.24 | 0.02 | -0.02 | -0.01 | |
| Sales general and administrative to revenue | 0.1 | 0.07 | 0.06 | 0.08 | 0.09 | |
| Research and developement to revenue | 0.04 | 0.11 | 0.09 | 0.16 | 0.16 | |
| Intangibles to total assets | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | |
| Capex to operating cash flow | -0.27 | -0.26 | -0.09 | -49.38 | -1.74 | |
| Capex to revenue | -0.02 | -0.04 | -0.02 | -0.02 | -0.03 | |
| Capex to depreciation | -0.38 | -0.8 | -0.47 | -0.32 | -0.34 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.61 | 0.43 | 0.61 | 0.7 | 0.79 | |
| ROIC | -0.04 | 0.04 | 0.03 | -0.04 | -0.06 | |
| Return on tangible assets | -0.03 | 0.02 | 0.04 | -0.05 | -0.08 | |
| Graham Net | 0.15 | 0.16 | 0.24 | 0.21 | 0.18 | |
| Working capital | 480.69M | 502.08M | 531.27M | 499.51M | 448.6M | |
| Tangible asset value | 602.84M | 610.55M | 641.02M | 605.49M | 546.85M | |
| Net current asset value | 480.31M | 500.34M | 530.27M | 467.91M | 420.24M | |
| Invested capital | 0.12 | 0.03 | 0.08 | 0.08 | 0.09 | |
| Average receivables | 148.07M | 144.4M | 154.57M | 155.32M | 136.02M | |
| Average payables | 39.79M | 61.91M | 60.49M | 59.2M | 56.73M | |
| Average inventory | 582.36M | 568.55M | 502.81M | 439.9M | 419.71M | |
| Days sales outstanding | 131.54 | 127.75 | 117.63 | 153.67 | 167.9 | |
| Days payables outstanding | 224.42 | 216.31 | 98.79 | 206.65 | 245.82 | |
| Days of inventory on hand | 2.15K | 1.9K | 769.87 | 1.46K | 1.91K | |
| Receivables turnover | 2.77 | 2.86 | 3.1 | 2.38 | 2.17 | |
| Payables turnover | 1.63 | 1.69 | 3.69 | 1.77 | 1.48 | |
| Inventory turnover | 0.17 | 0.19 | 0.47 | 0.25 | 0.19 | |
| ROE | -0.05 | 0.02 | 0.04 | -0.06 | -0.1 | |
| Capex per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 | |
| Net income per share | 0 | -0.01 | -0.02 | -0.02 | -0.01 | |
| Operating cash flow per share | 0 | -0.01 | -0.02 | 0 | 0 | |
| Free cash flow per share | 0 | -0.01 | -0.02 | 0 | 0 | |
| Cash per share | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | |
| Book value per share | 0.55 | 0.54 | 0.52 | 0.5 | 0.5 | |
| Tangible book value per share | 0.54 | 0.53 | 0.51 | 0.5 | 0.5 | |
| Share holders equity per share | 0.55 | 0.54 | 0.52 | 0.5 | 0.5 | |
| Interest debt per share | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | |
| Market cap | 3.08B | 3.26B | 3.05B | 2.67B | 2.94B | |
| Enterprise value | 3.1B | 3.28B | 3.07B | 2.69B | 2.97B | |
| P/E ratio | -318.08 | -55.68 | -36.07 | -35.43 | -132.83 | |
| Price to sales ratio | 39.35 | 44.39 | 53.45 | 41.41 | 50.31 | |
| POCF ratio | -1.27K | -222.7 | -144.28 | -1.19K | -10.92K | |
| PFCF ratio | -1.25K | -483.54 | -142.92 | -836.92 | -4.83K | |
| P/B Ratio | 5.39 | 5.86 | 5.66 | 5.13 | 5.73 | |
| PTB ratio | 5.39 | 5.86 | 5.66 | 5.13 | 5.73 | |
| EV to sales | 39.63 | 44.67 | 53.86 | 41.83 | 50.8 | |
| Enterprise value over EBITDA | 45.73K | -394.48 | -186.26 | -192.73 | -834.9 | |
| EV to operating cash flow | -1.28K | -224.11 | -145.38 | -1.2K | -11.02K | |
| EV to free cash flow | -1.26K | -486.58 | -144.01 | -845.38 | -4.88K | |
| Earnings yield | 0 | 0 | -0.01 | -0.01 | 0 | |
| Free cash flow yield | 0 | 0 | -0.01 | 0 | 0 | |
| Debt to equity | 0.09 | 0.09 | 0.09 | 0.09 | 0.1 | |
| Debt to assets | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | |
| Net debt to EBITDA | 322.93 | -2.47 | -1.41 | -1.93 | -7.97 | |
| Current ratio | 4.93 | 4.86 | 4.86 | 4.2 | 4.44 | |
| Interest coverage | -0.94 | 13.22 | -37.07 | 93.12 | -3.89 | |
| Income quality | 1 | 1 | 1 | 0.12 | 0.05 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.08 | -0.01 | -0.01 | -0.01 | -0.03 | |
| Sales general and administrative to revenue | 0.43 | -0.3 | 0.22 | 0.09 | 0.51 | |
| Research and developement to revenue | 0.19 | -0.03 | 0.13 | 0.13 | 0.11 | |
| Intangibles to total assets | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | |
| Capex to operating cash flow | 0.01 | -0.54 | 0.01 | 0.42 | 1.26 | |
| Capex to revenue | 0 | 0.11 | 0 | -0.01 | -0.01 | |
| Capex to depreciation | -0.01 | 1.46 | -0.04 | -0.19 | 0.03 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.17 | 0.42 | 0.49 | 0.46 | 0.25 | |
| ROIC | 0 | -0.02 | -0.03 | -0.03 | -0.01 | |
| Return on tangible assets | 0 | -0.02 | -0.03 | -0.03 | -0.01 | |
| Graham Net | 0.18 | 0.18 | 0.16 | 0.15 | 0.15 | |
| Working capital | 460.95M | 448.6M | 432.51M | 418.25M | 422.15M | |
| Tangible asset value | 558.55M | 546.85M | 527.32M | 509.91M | 510.16M | |
| Net current asset value | 428.59M | 420.24M | 404.06M | 389.76M | 393.47M | |
| Invested capital | 0.09 | 0.09 | 0.09 | 0.09 | 0.1 | |
| Average receivables | 113.5M | 120.69M | 114.46M | 106.13M | 105.97M | |
| Average payables | 63.16M | 58.25M | 54.09M | 60.56M | 62.59M | |
| Average inventory | 429.18M | 417.31M | 409.69M | 413.26M | 415.96M | |
| Days sales outstanding | 134.73 | 152.12 | 165.2 | 150.4 | 160.43 | |
| Days payables outstanding | 259.08 | 234.56 | 276.33 | 349.33 | 311.25 | |
| Days of inventory on hand | 1.73K | 1.82K | 2.04K | 2.21K | 2.17K | |
| Receivables turnover | 0.67 | 0.59 | 0.54 | 0.6 | 0.56 | |
| Payables turnover | 0.35 | 0.38 | 0.33 | 0.26 | 0.29 | |
| Inventory turnover | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | |
| ROE | 0 | -0.03 | -0.04 | -0.04 | -0.01 | |
| Capex per share | 0 | 0.01 | 0 | 0 | 0 |
000518.SZ Frequently Asked Questions
What is Jiangsu Sihuan Bioengineering Co., Ltd stock symbol ?
Jiangsu Sihuan Bioengineering Co., Ltd is a CN stock and trading under the symbol 000518.SZ
What is Jiangsu Sihuan Bioengineering Co., Ltd stock quote today ?
Jiangsu Sihuan Bioengineering Co., Ltd stock price is $2.07 today.
Is Jiangsu Sihuan Bioengineering Co., Ltd stock public?
Yes, Jiangsu Sihuan Bioengineering Co., Ltd is a publicly traded company.
Company Profile
- Volume Average 35.05M
- Market Capitalization 2.38B
- Employee 250
- CEO Mr. Yu Guo
- Headquarters Jiangyin,CN
- IPO Date 1993-09-08
-
Website
https://www.000518shsw.com/shsw 
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.
